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1 |  INTRODUCTION
Statins are commonly prescribed for atherosclerotic disease, 
and although generally safe, their use has been associated 
with serious muscular involvement.1 The spectrum of statin- 
associated neuromuscular involvement ranges from myalgia 
with increase of creatine kinase (CK), to severe conditions in-
cluding necrotizing autoimmune myopathy (NAM), and less 
commonly, myasthenia gravis (MG).1- 3
Serum myositis- specific autoantibodies associated with 
NAM include anti- 3- hydroxy- 3- methylglutarylcoenzyme- A 
reductase (HMGCR) and antisignal recognition particle 
(SRP).4 Anti- HMGCR myopathy is characterized by severe, 
rapidly progressive proximal muscle weakness along with 
dysphagia in 16%- 30% of the patients, and elevated serum 
CK levels.5,6 Muscle biopsy shows necrosis with scarce or 
no inflammation. In most patients with a history of statin ex-
posure, symptoms do not resolve after withdrawing the drug, 
and only a prompt immunosuppressive treatment leads to 
clinical improvement.4,7
While lines of evidences suggest a causal relationship be-
tween NAM and statin intake, MG is not currently included 
among adverse drug reactions to statins and in a dispropor-
tionality analysis of nearly 4,000 reports mentioning MG, a 
weak potential signal was found linking statins and MG.8 On 
the other hand, there have been a number of literature and 
postmarketing pharmacovigilance reports suggesting that 
statins may induce, unmask or exacerbate ocular or gener-
alized MG, either seropositive or seronegative for antibodies 
against acetylcholine receptors (AchR).3,9- 14
We report on a patient treated with statin and ezetimibe 
who developed NAM and generalized MG which responded 
favorably to immunosuppressive therapy.
2 |  CASE REPORT
A 65- year- old male complained of progressive lower limb 
weakness and calf muscle pain. No autoimmune or hereditary 
neuromuscular diseases were referred. His medical history 
was remarkable for arterial hypertension, mild carotid ather-
osclerosis, subclinical hypothyroidism, and hyperlipidemia. 
Eight months before admission the patient had an acute 
myocardial infarct for which percutaneous transluminal 
Received: 1 October 2020 | Revised: 26 December 2020 | Accepted: 17 January 2021
DOI: 10.1002/ccr3.3925  
C A S E  R E P O R T
Statin- associated necrotizing autoimmune myopathy with 
concurrent myasthenia gravis
Emma Frasson1  |   Marco Simonetto1 |   Laura Bertolasi2 |   Giorgio Caneve1 |   
Cristina Vilotti1 |   Giampietro Ruzza1 |   Anna Perelli1 |   Maria Grazia Piccinno1 |   
Salvatore Monaco2
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
1Department of Neurology, AULSS 6 
Euganea, Cittadella Hospital, Padua, Italy
2Section of Clinical Neurology, Department 
of Neurosciences, Biomedicine and 
Movement Sciences, University of Verona, 
Verona, Italy
Correspondence
Emma Frasson, Department of Neurology, 
AULSS 6 Euganea, Via Casa di Ricovero, 
40, 35013 Cittadella, Padua, Italy.
Email: emma.frasson@aulss6.veneto.it
Abstract
Statin treatment has been associated with necrotizing autoimmune myopathy and has 
been linked to myasthenia gravis. We present an unprecedented clinical challenge 
with both disorders occurring in a patient treated with statins few months earlier.
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coronary angioplasty with placement of two stents in main 
coronary arteries was performed. Medical therapy at dis-
charge included ramipril, bisoprolol, ticagrelor, aspirin, 
and high- intensity statin treatment with 80 mg atorvastatin. 
Six months later atorvastatin was switched to rosuvastatin/
ezetimibe 20  mg/10  mg combination therapy because the 
patient reported mild weakness and fatigue. The treatment 
with rosuvastatin/ezetimibe was discontinued 2 weeks prior 
to admission because of worsening weakness and increased 
serum CK level (12 309 IU/L; reference range <223 IU/L).
On admission, 3 months after the onset of symptoms, the 
patient complained of easy fatigability and difficulties in get-
ting up from a chair and walking; his muscle strength was 
symmetrically reduced at proximal (3/5 by MRC) and distal 
(4/5 by MRC) segments of all limbs; arm and thigh muscles 
were hypotrophic. The patient had mild facial and palatal 
weakness, severe dysphonia, and dysphagia. Sensation and 
deep tendon reflexes were normal. Severity of weakness 
fluctuated during the day being worse at evening. During 
hospitalization, the patient developed dyspnea at rest with 
decreased oxygen saturation values of 90% in room air.
Serum CK was 32  000  IU/L, AST 950  IU/L (refer-
ence range: 5- 38  IU/L), ALT 655  IU/L (reference range 
5- 41  IU/L), LDH 1100 (reference: <248  IU/L). Anti- AchR 
turned out to be increased to 8.9 nmol/L (NV < 0.5), and anti- 
HMGCR antibody titer was 255.2  IU/mL (reference range, 
<19  IU/mL). ANA, anti- ds- DNA, anti- SSA, and anti- SSB 
were negative. Among myositis- associated autoantibodies, 
F I G U R E  1  Muscle MRI of lower 
limbs. Coronal T1- weighted images (A) 
reveal muscle atrophy and hyperintensity 
reflecting connective tissue and fatty 
replacement (arrows). Coronal short- tau 
inversion recovery (STIR) sequences (B) 
show edema and asymmetrically increased 
signals in muscle compartments (arrows). 
Axial T2- weighted sequences show atrophy 
in proximal (C) and in the distal (D) thigh 
muscles. (semimembranosus = SM). PEC, 
denotes pectineus, PSOAS, ileopsoas, ADB, 
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a moderate positivity for anti- Ro- 52 was detected by im-
munoblotting. Extensive electrodiagnostic investigations, 
including bilateral median, ulnar, radial, peroneal, and tib-
ial motor- conduction studies and median, ulnar, radial, and 
sural sensory- conduction studies, were normal. Needle elec-
tromyography (EMG) studies showed a myopathic pattern 
on voluntary recruitment with abnormal spontaneous activ-
ity in proximal limb muscles, including trapezius, deltoid, 
biceps, and vastus lateralis. Single- fiber EMG (SF- EMG) 
performed during voluntary contraction of the extensor dig-
itorum communis at 20 recording sites showed a mean jit-
ter of 65.5 ± 40.2 µs (range 39.7- 196 µs), in the presence of 
blockings.
A lower limb MRI revealed asymmetric edema and at-
rophy of proximal and distal thigh muscles (Figure  1). A 
left vastus lateralis muscle biopsy showed slight variation 
in fiber caliber, with few atrophic fibers, randomly distrib-
uted necrotic myofibers, either hyalinized or myophagocytic, 
and rare basophilic fibers, but not inflammatory infiltrates. 
Echocardiogram and total body CT scan were normal.
The patient was treated with IVIg (0.4 g/kg die) for 5 days, 
prednisone 1  mg/kg, and azathioprine 100  mg/die. After 
8  days, azathioprine was discontinued because the patient 
had a diffuse rash, and intramuscular injections of metho-
trexate 15 mg/week were given; in addition, piridostigmine 
at a dose of 30 mg three times a day was started.
The patient gradually improved and after 4  months of 
treatment, he could walk and feed unaided. CK was 241 IU/L, 
anti- HMGCR 25  IU/mL, and anti- AchR 9.3 nmol/L. A re-
peated EMG recorded a myopathic pattern without denerva-
tion. Six months later, prednisone was tapered to 15 mg/die 
and methotrexate to 10  mg/week because of persistent im-
provement of symptoms.
3 |  DISCUSSION
To our knowledge, this is the first reported patient with statin- 
associated NAM with anti- HMGCR IgG occurring concomi-
tantly with anti- AchR seropositive MG.
As reported in previous cases, the duration of statin ex-
posure before the onset of NAM ranges from few months to 
2 years, and the course of the disease is remarkably varied, 
usually within months and years.15 In addition, while the 
majority of patients with NAM require immunosuppressive 
and/or immunomodulatory medications, subjects with mild 
weakness may have spontaneous remission. The latter evo-
lution is at variance with the disappearance of minor symp-
toms, such as myalgias and cramps, which cease a few weeks 
after discontinuation of statins.15
The variability in clinical presentation and outcome sug-
gests that immune- mediated muscle injury and reversible 
statin myotoxicity might contribute to varying degrees of 
perceived and objective weakness in a given patient, and 
also provides an explanation for the persistence of muscular 
involvement months after statin withdrawal. In the present 
case, all clinical and paraclinical features observed at dis-
ease onset and evolution are consistent with statin- associated 
NAM, but not myotoxicity.
However, in our patient distinctive clinical features, 
such as fatigable and fluctuating muscle weakness, dys-
phonia, facial and palatal weakness, dysphagia, and respi-
ratory distress, suggested a coexistent dysfunction of the 
neuromuscular junction. Indeed, beside the occurrence of 
dysphagia occurring in 16%- 30% of patients with NAM,4 
only one patient with facial weakness has been reported in 
revised case series, while there is no consistent evidence 
of respiratory involvement.16 The clinical suspicion of MG 
was further supported by neurophysiological and serolog-
ical findings. In our case, the possibility of a subclinical 
form of MG exacerbated by statin treatment is not consis-
tent with previous observations reporting MG worsening 
within 1- 16 weeks of statin treatment.17 On the contrary, 
in statin- associated MG the time interval from the initia-
tion of statins to the onset of MG ranges from 6  months 
to 6 years.13 The most likely hypothesis to account for the 
coexistence of both NAM and MG in our patient is based 
on the immunomodulatory effects of statins,5,18 which 
may trigger an increased immunogenicity to neuromuscu-
lar peptides in subjects with distinctive HLA haplotypes. 
These drugs are recognized to induce other autoimmune 
disorders such as a lupus- like syndrome, myositis, and 
immune hepatitis.19 The mechanisms underlying the pro-
duction of antibodies to HMGCR and AchR, in addition to 
anti- Ro- 52, are unknown, although autoimmunity could be 
driven by drug- induced loss of immune tolerance.
Timely immunosuppressive treatment in statin- exposed 
patients usually leads to muscle strength improvement and 
decrease in anti- HMGCR and CK levels, as we observed 
in our patient.1 This is keeping with previous observations 
showing a strict correlation among anti- HMGCR titer, CK 
level, and muscle weakness.4 Notably, in refractory cases 
or in patients receiving delayed treatment, accelerated mus-
cle atrophy represents the major contributor to long- term 
disability.7
In conclusion, clinicians should be alerted to the possible 
association between statin exposure and incident NAM/MG 
in order to discontinue the drug and promptly begin an immu-
nosuppressive treatment.
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